-
10.03.2023 | CARB-X is funding a University of Melbourne research team to develop an oral therapeutic to treat drug-resistant community-acquired bacterial pneumonia
CARB-X is awarding US$1.75 million to the University of Melbourne at the Doherty Institute to develop an oral therapeutic that restores the activity of workhorse antibiotics used to treat community-acquired bacterial pneumonia (CABP).
-
08.21.2023 | G20 Health Ministers highlight urgent need to develop new antimicrobials to tackle resistance
The Global Antibiotic Research & Development Partnership (GARDP) and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) jointly welcome the G20 Health Ministers’ Outcome Document, which underscores the urgent need to develop new antimicrobials, including antibiotics, to help tackle the growing global health crisis caused by antimicrobial resistance (AMR).
-
08.10.2023 | UK government bolsters partnership with CARB-X
Through its Global AMR Innovation Fund (GAMRIF), the UK government has committed up to £24 million to CARB-X over the next four years to support the continued early development of innovative products that aim to prevent, diagnose and treat drug-resistant bacterial infections.
-
08.03.2023 | Government of Canada to join CARB-X partnership
The Public Health Agency of Canada (PHAC) plans to award $6.3 million to CARB-X over the next two years, with the objectives of advancing the development of new projects aimed at preventing, diagnosing and treating the most dangerous drug-resistant infections, and supporting a stronger antibacterial R&D ecosystem in Canada.
-
07.27.2023 | German government renews commitment to CARB-X
Germany’s Federal Ministry of Education and Research (BMBF) has committed an additional €41 million to CARB-X and its Global Acceleration Network over the next 4 years.
-
06.07.2023 | CARB-X welcomes renewed G7 commitments to support antibacterial innovation
The importance of supporting CARB-X as a global push incentive that coordinates and accelerates much-needed antibacterial innovation featured prominently on the G7 agenda during the past month in Japan.
-
04.27.2023 | CARB-X 2021-22 annual report launched today
CARB-X published its 2021-2022 annual report today. The report highlights achievements, including CARB-X projects in clinical development, new products on the market, renewed funding commitments, open funding rounds, and Portfolio Acceleration Tools, a series of research projects led by CARB-X to support multiple product developers.
-
03.09.2023 | CARB-X announces appointment of Dan Burgess as Board Chair
With unanimous approval, CARB-X’s governing body, the Joint Oversight Board (JOB), voted to appoint Dan Burgess, AB, MBA, as the first Independent Chair of the JOB. The JOB oversees the strategy, scope and budget of CARB-X. The new role of independent chair further strengthens CARB-X governance and brings an industry voice and perspective to the international partnership.
Toggle navigation